The special case of gene therapy pricing (original) (raw)

Nature Biotechnology volume 32, pages 874–876 (2014)Cite this article

Subjects

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Wilson, J.M. Genet. Eng. News 33, 62 (2013).
    Article Google Scholar
  2. Kohn, D.B., Pai, S.Y. & Sadelain, M. Biol. Blood Marrow Transplant. 19, S64–S69 (2013).
    Article CAS Google Scholar
  3. Xiao, P.J., Lentz, T.B. & Samulski, R.J. Ther. Deliv. 3, 835–856 (2012).
    Article CAS Google Scholar
  4. Maguire, A.M. et al. N. Engl. J. Med. 358, 2240–2248 (2008).
    Article CAS Google Scholar
  5. Nathwani, A.C. et al. N. Engl. J. Med. 365, 2357–2365 (2011).
    Article CAS Google Scholar
  6. Buchlis, G. et al. Blood 119, 3038–3041 (2012).
    Article CAS Google Scholar
  7. Bryant, L.M. et al. Hum. Gene Ther. Clin. Dev. 24, 55–64 (2013).
    Article CAS Google Scholar
  8. Anonymous. Delivering gene therapy to patients. Presented at the Jefferies 2014 Global Healthcare Conference, June 2–5, 2014, New York.
  9. Kesselheim, A.S. Milbank Q. 89, 450–502 (2011).
    Article Google Scholar
  10. Nathan, D.G. & Orkin, S.H. Genome Med. 1, 114 (2009).
    Article Google Scholar
  11. Berndt, E.R. & Hurvitz, J.A. Health Aff. (Millwood) 24, 653–665 (2005).
    Article Google Scholar
  12. Kremer, M. in Innovation Policy and the Economy (eds. Jaffe, A., Lerner, J. & Stern, S.) (MIT Press, Boston, 2001).
    Google Scholar
  13. National Library of Medicine. Genetics Home Reference (National Library of Medicine, 2014).
  14. Brennan T. & Shrank W. J. Am. Med. Assoc. 312, 593–594 (2014).
    Article CAS Google Scholar
  15. Bordonaro, G. Hartfordbusiness.com, vol. 2014 Cigna, Merck ink pay-for-performance deal. (The Hartford Business Journal, 2009). <http://www.hartfordbusiness.com/article/20090525/PRINTEDITION/305259968/cigna-merck-ink-pay-for-performance-deal>
  16. Gostin, L.O., Hyman, D., Jacobson, P.D. & Studdert, D. Law and the Health System: Casebook Series (Foundation Press, 2014).
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Troyen A. Brennan is at CVS Caremark, Woonsocket, Rhode Island, USA.,
    Troyen A Brennan
  2. James M. Wilson is at the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,
    James M Wilson

Authors

  1. Troyen A Brennan
  2. James M Wilson

Corresponding author

Correspondence toTroyen A Brennan.

Ethics declarations

Competing interests

J.M.W. is an advisor to and a founder of ReGenX Biosciences and Dimension Therapeutics; he also holds equity in and receives a grant from these companies. In addition, he is an inventor on patents licensed to various biopharmaceutical companies, including affiliates of ReGenX Holdings, and consults on an ad hoc basis for several biopharmaceutical companies. He is an inventor on the vector used in the Glybera product. T.A.B. is employed by and holds stock in CVS Caremark.

Rights and permissions

About this article

Cite this article

Brennan, T., Wilson, J. The special case of gene therapy pricing.Nat Biotechnol 32, 874–876 (2014). https://doi.org/10.1038/nbt.3003

Download citation

This article is cited by